Arrowhead had been working with Janssen since 2018 on the hepatitis B medicine JNJ-3989. Now, GSK has been revealed as Arrowhead’s new partner for the program—although the two have an existing ...

Arrowhead finds RNAi kidney disease candidate is well tolerated in phase 1/2 IgAN trial cohort. By Gabrielle Masson Mar 10, 2025 11:55am. Arrowhead Pharmaceuticals RNA interference ...